Mitochondrial Biology and Experimental Therapeutics

Target Mitochondria.- SECTION I-Mitochondrial Biology.- Introduction: Mitochondria: the cell furnace.- MItochondria: Where are They Coming From?.- Mitochondrial Dynamics: A journey from Mitochondrial Morphology to MItochondrial Function and Quality.- Mitochondrial ROS, Oxidative Stress.and Aging- The Mitochondrial Permeability Transition Pore.- Mitochondrial Regulation of Cell Death.- MItochondria in Liver Diseases.- Mitochondria in Liver Regeneration,Energy Metabolism, and Posthepatectomy Liver Dysfunction.- MItochondrial Remodeling in Cancer.- Mitochondria in Kidney Disease.- CNS diseases and disruption of Mitochondria.- Mitochondrial disruption in cardiovascular diseases.- .Drug-inducing Mitochondrial Toxicity.- MItochondrial DNA: Functions and Role in Acquired Diseases.- SECTION II-MItochondrial Therapeutics: From the Bench to Industry and Patient.- The Evolution of Mitochondrial Toxicity Assessment in Industry.- Designing Mitochondrial-Active Molecules: The Road to MitoQ and Beyond.- Recovering Mitochondrial Function in Patients' Fibroblasts.- Targeting Mitochondria with Sweat: Improving Mitochondrial Function with Physical Activity.- Modulation of Cell Fate by Tauroursodexycholic Acid: All Paths Lead to Mitochondria.- Pharmacological Targeting of the Mitchondrial Permeability Transition Pore.- Strategies to Preserve/Improve Mitochondrial Function in Organ Preservation Solutions.- MItochondrial Targeted Redox Active Compounds and the Astrocytemotoneuron Axis: relevance for the Treatment of Amyotrophic Lateral Sclerosis.- Targeting the Mitochondrial Genome Through a Nanocarrier and the Regulation of the Mitochondrial Gene Experssion.- Mitochoncrial Dysfunction and Chronic Disease: Treatment with Membrane Lipid Replacement and other Natural Supplements.- Development of Mitochondrial-Directed Plastoquinones.- Targeted Mitochondrial Genome Editing.- Targeting Therpeutic Nucleic Acids into Mitochondria: A Long Challenge.- Cell Permeable Peptides Targeting

Paulo J. Oliveira is recognized for his work as the Coordinator of the Mitochondrial, Metabolism, and Disease Group at the Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Portugal and is the current Vice-President of the European Society of Clinical Investigation (ESCI). He has previously spent some time at the University of Minnesota Medical School, Duluth, investigating the mitochondrial mechanisms of anthracycline-induced selective cardiotoxicity. Throughout his career, he has been involved in projects in which the objective was to advance fundamental knowledge and methodological aspects of mitochondrial research. His current research interests include the role of mitochondria in cardiovascular and liver diseases, the relationship between mitochondrial remodeling and (cancer) stem cell biology, development of novel mitochondrial-targeted therapeutics, as well as the mechanisms of drug-related mitochondrial toxicity. Dr. Oliveira has co-authored close to 200 publications focusing on mitochondrial research.